ALK-Abello's Grazax approved in Europe
Authorities in 27 European countries have now approved ALK-Abello's tablet-based vaccine against grass pollen allergy, Grazax - the first allergy tablet to address the underlying cause of the disease. The Denmark-based company expects to launch this on the first European markets by the end of 2006, ahead of the 2007 pollen season.
"We are very pleased to complete the European Mutual Recognition Procedure with such a positive result. This is a decisive step towards the launch of Grazax. We now look forward to ensuring many more grass-allergic patients in Europe benefit from Grazax treatment, with reduced allergy symptoms and improved quality of life," says Jens Bager, the firm's chief executive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze